NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing ... Angel Pharmaceuticals was launched through a collaboration with U.S.-based Corvus and investments from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback